547 related articles for article (PubMed ID: 22067397)
1. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
Chawla SP; Staddon AP; Baker LH; Schuetze SM; Tolcher AW; D'Amato GZ; Blay JY; Mita MM; Sankhala KK; Berk L; Rivera VM; Clackson T; Loewy JW; Haluska FG; Demetri GD
J Clin Oncol; 2012 Jan; 30(1):78-84. PubMed ID: 22067397
[TBL] [Abstract][Full Text] [Related]
2. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
[TBL] [Abstract][Full Text] [Related]
3. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.
Mita MM; Gong J; Chawla SP
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829
[TBL] [Abstract][Full Text] [Related]
4. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.
Colombo N; McMeekin DS; Schwartz PE; Sessa C; Gehrig PA; Holloway R; Braly P; Matei D; Morosky A; Dodion PF; Einstein MH; Haluska F
Br J Cancer; 2013 Mar; 108(5):1021-6. PubMed ID: 23403817
[TBL] [Abstract][Full Text] [Related]
5. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.
Mita MM; Poplin E; Britten CD; Tap WD; Rubin EH; Scott BB; Berk L; Rivera VM; Loewy JW; Dodion P; Haluska F; Sarantopoulos J; Mita A; Tolcher A
Ann Oncol; 2013 Apr; 24(4):1104-11. PubMed ID: 23211938
[TBL] [Abstract][Full Text] [Related]
6. Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.
Oza AM; Pignata S; Poveda A; McCormack M; Clamp A; Schwartz B; Cheng J; Li X; Campbell K; Dodion P; Haluska FG
J Clin Oncol; 2015 Nov; 33(31):3576-82. PubMed ID: 26077241
[TBL] [Abstract][Full Text] [Related]
7. A role for maintenance therapy in managing sarcoma.
Ray-Coquard I; Le Cesne A
Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
[TBL] [Abstract][Full Text] [Related]
8. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.
Dancey JE; Monzon J
Future Oncol; 2011 Jul; 7(7):827-39. PubMed ID: 21732754
[TBL] [Abstract][Full Text] [Related]
9. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.
Schuetze SM; Zhao L; Chugh R; Thomas DG; Lucas DR; Metko G; Zalupski MM; Baker LH
Eur J Cancer; 2012 Jun; 48(9):1347-53. PubMed ID: 22525224
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.
Pearson AD; Federico SM; Aerts I; Hargrave DR; DuBois SG; Iannone R; Geschwindt RD; Wang R; Haluska FG; Trippett TM; Geoerger B
Oncotarget; 2016 Dec; 7(51):84736-84747. PubMed ID: 27713169
[TBL] [Abstract][Full Text] [Related]
11. Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.
Seiler M; Ray-Coquard I; Melichar B; Yardley DA; Wang RX; Dodion PF; Lee MA
Clin Breast Cancer; 2015 Feb; 15(1):60-5. PubMed ID: 25239224
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
13. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG
Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833
[TBL] [Abstract][Full Text] [Related]
14. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.
Amato RJ; Wilding G; Bubley G; Loewy J; Haluska F; Gross ME
Clin Genitourin Cancer; 2012 Dec; 10(4):232-8. PubMed ID: 22695254
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.
Gore L; Trippett TM; Katzenstein HM; Boklan J; Narendran A; Smith A; Macy ME; Rolla K; ; Narashimhan N; Squillace RM; Turner CD; Haluska FG; Nieder M
Clin Cancer Res; 2013 Jul; 19(13):3649-58. PubMed ID: 23659969
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Yoo C; Lee J; Rha SY; Park KH; Kim TM; Kim YJ; Lee HJ; Lee KH; Ahn JH
Invest New Drugs; 2013 Dec; 31(6):1602-8. PubMed ID: 24037083
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.
Frappaz D; Federico SM; Pearson AD; Gore L; Macy ME; DuBois SG; Aerts I; Iannone R; Geschwindt R; Van Schanke A; Wang R; Geoerger B
Eur J Cancer; 2016 Jul; 62():9-17. PubMed ID: 27185573
[TBL] [Abstract][Full Text] [Related]
18. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.
Seki Y; Yamamoto N; Tamura Y; Goto Y; Shibata T; Tanioka M; Asahina H; Nokihara H; Yamada Y; Shimamoto T; Noguchi K; Tamura T
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1099-105. PubMed ID: 22143378
[TBL] [Abstract][Full Text] [Related]
19. Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?
Garrido-Laguna I; Janku F
J Clin Oncol; 2012 Mar; 30(8):892-3. PubMed ID: 22291080
[No Abstract] [Full Text] [Related]
20. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
